Level Four Advisory Services’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Level Four Advisory Services’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,947	Closed	-$824K	–	680
2022 Q1	$824K	Buy	6,947 +204	+3%	+$25.4K	0.06%	281
2021 Q4	$929K	Buy	6,743 +3,184	+89%	+$405K	0.07%	271
2021 Q3	$494K	Buy	+3,559	New	+$444K	0.05%	294

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Level Four Advisory Services's BHVN Position: Q2 2022 in Review

Level Four Advisory Services sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 6,947 shares — an estimated $824K sold.

Level Four Advisory Services first reported a position in BHVN in Q3 2021 and held it in 3 quarters. The position peaked at $929K in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Level Four Advisory Services reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Level Four Advisory Services sold 6,947 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $824K.
Level Four Advisory Services first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 3 quarters.
Level Four Advisory Services's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $929K in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Level Four Advisory Services's 13F filing for Q2 2022, filed 8 Aug 2022.